Vetr Inc. Upgrades Allergan PLC (AGN) to Strong-Buy
Allergan PLC (NYSE:AGN) was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued on Monday. The brokerage presently has a $285.60 price target on the stock. Vetr‘s target price indicates a potential upside of 25.51% from the stock’s previous close.
A number of other equities analysts also recently issued reports on the company. Citigroup Inc. restated a “buy” rating and set a $285.00 price objective (down from $360.00) on shares of Allergan PLC in a research report on Thursday, April 7th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Allergan PLC in a research note on Wednesday, July 6th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $354.00 target price on shares of Allergan PLC in a research note on Tuesday, April 5th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Allergan PLC in a research note on Saturday, June 25th. Finally, Zacks Investment Research raised Allergan PLC from a “hold” rating to a “buy” rating and set a $274.00 target price for the company in a research note on Friday, July 15th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Allergan PLC has an average rating of “Buy” and a consensus price target of $302.23.
Shares of Allergan PLC (NYSE:AGN) traded down 2.07% during midday trading on Monday, hitting $227.55. The stock had a trading volume of 3,828,801 shares. The firm has a market cap of $90.10 billion, a P/E ratio of 21.67 and a beta of 0.81. Allergan PLC has a 52 week low of $195.50 and a 52 week high of $322.68. The company’s 50 day moving average is $238.01 and its 200 day moving average is $238.04.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/16/vetr-inc-upgrades-allergan-plc-agn-to-strong-buy.html
Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The company earned $3.68 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the company earned $4.41 earnings per share. The firm’s revenue was up 1.0% compared to the same quarter last year. On average, equities analysts predict that Allergan PLC will post $14.00 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in AGN. Barnett & Company Inc. bought a new position in shares of Allergan PLC during the first quarter valued at $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in shares of Allergan PLC during the second quarter valued at $125,000. Trust Co. of Vermont boosted its position in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Carroll Financial Associates Inc. boosted its position in shares of Allergan PLC by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock valued at $127,000 after buying an additional 226 shares during the period. Finally, Ropes Wealth Advisors LLC boosted its position in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock valued at $133,000 after buying an additional 58 shares during the period. Institutional investors own 85.19% of the company’s stock.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.